全文获取类型
| 收费全文 | 926210篇 |
| 免费 | 67565篇 |
| 国内免费 | 1336篇 |
专业分类
| 耳鼻咽喉 | 12947篇 |
| 儿科学 | 24303篇 |
| 妇产科学 | 23228篇 |
| 基础医学 | 132107篇 |
| 口腔科学 | 28276篇 |
| 临床医学 | 80090篇 |
| 内科学 | 181926篇 |
| 皮肤病学 | 19216篇 |
| 神经病学 | 71746篇 |
| 特种医学 | 36766篇 |
| 外国民族医学 | 79篇 |
| 外科学 | 151735篇 |
| 综合类 | 18007篇 |
| 现状与发展 | 1篇 |
| 一般理论 | 234篇 |
| 预防医学 | 61291篇 |
| 眼科学 | 21256篇 |
| 药学 | 72353篇 |
| 3篇 | |
| 中国医学 | 2119篇 |
| 肿瘤学 | 57428篇 |
出版年
| 2018年 | 8963篇 |
| 2017年 | 7029篇 |
| 2016年 | 7762篇 |
| 2015年 | 8862篇 |
| 2014年 | 11985篇 |
| 2013年 | 17502篇 |
| 2012年 | 24086篇 |
| 2011年 | 25035篇 |
| 2010年 | 14803篇 |
| 2009年 | 14265篇 |
| 2008年 | 24604篇 |
| 2007年 | 25695篇 |
| 2006年 | 26485篇 |
| 2005年 | 25430篇 |
| 2004年 | 24547篇 |
| 2003年 | 23544篇 |
| 2002年 | 23094篇 |
| 2001年 | 54663篇 |
| 2000年 | 56446篇 |
| 1999年 | 46758篇 |
| 1998年 | 10271篇 |
| 1997年 | 8983篇 |
| 1996年 | 9130篇 |
| 1995年 | 8879篇 |
| 1994年 | 8250篇 |
| 1993年 | 7568篇 |
| 1992年 | 35460篇 |
| 1991年 | 33909篇 |
| 1990年 | 32724篇 |
| 1989年 | 31859篇 |
| 1988年 | 28973篇 |
| 1987年 | 28242篇 |
| 1986年 | 26275篇 |
| 1985年 | 25138篇 |
| 1984年 | 17816篇 |
| 1983年 | 15118篇 |
| 1982年 | 7766篇 |
| 1981年 | 6736篇 |
| 1979年 | 15759篇 |
| 1978年 | 10582篇 |
| 1977年 | 9025篇 |
| 1976年 | 7860篇 |
| 1975年 | 8616篇 |
| 1974年 | 10456篇 |
| 1973年 | 9850篇 |
| 1972年 | 9354篇 |
| 1971年 | 8847篇 |
| 1970年 | 8414篇 |
| 1969年 | 7916篇 |
| 1968年 | 7197篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
51.
Clinical and Translational Oncology - The specific association between PTEN deletion or ERG rearrangement and the recurrence of prostate cancer (PC) treated with radical prostatectomy (RP) or... 相似文献
52.
53.
54.
Emarene Kalaw Malcolm Lim Jamie R. Kutasovic Anna Sokolova Lucinda Taege Kate Johnstone James Bennett Jodi M. Saunus Colleen Niland Kaltin Ferguson Irma Gresshoff Mark Bettington Nirmala Pathmanathan Gary M. Tse David Papadimos Rajadurai Pathmanathan Gavin Harris Rin Yamaguchi Puay Hoon Tan Stephen Fox Sandra A. O’Toole Peter T. Simpson Sunil R. Lakhani Amy E. McCart Reed 《British journal of cancer》2020,123(11):1665
55.
Nicole D. Facompre Pavithra Rajagopalan Varun Sahu Alexander T. Pearson Kathleen T. Montone Claire D. James Frederico O. Gleber-Netto Gregory S. Weinstein Jalal Jalaly Alexander Lin Anil K. Rustgi Hiroshi Nakagawa Joseph A. Califano Curtis R. Pickering Elizabeth A. White Bradford E. Windle Iain M. Morgan Roger B. Cohen Phyllis A. Gimotty Devraj Basu 《International journal of cancer. Journal international du cancer》2020,147(11):3236-3249
56.
Background
Though the optimal treatment regimen in older patients with glioblastoma multiforme (GBM) remains to be established, multiple randomized studies have supported the use of hypofractionated (1–3?weeks) versus traditional regimens (6?weeks). Here we examine hypofractionated regimen practice patterns among older patients with GBM.Methods
We used the National Cancer Database and included individuals aged ≥65?years with GBM diagnosed from 2005 to 2014 undergoing biopsy/resection followed by chemotherapy and radiation initiated ≤8-weeks of diagnosis. We defined traditional fractionation as ≤200?cGy and hypofractionation as >200?cGy. We compared patient characteristics using a chi-squared test and multivariable logistic regression. We compared 90-day mortality rates following initiation of radiation using the Wald statistic in propensity score matched cohorts.Results
The final cohort included 14,931 individuals with 1524 undergoing hypofractionated treatment. From 2005 to 2014 hypofractionated utilization rates were 7%, 9%, 13%, and 18% among those 65–69, 70–74, 75–79, and ≥80?years of age, respectively. Patients treated at an academic/research center had a >60% increased odds (OR, 1.61; 95% CI, 1.43–1.81) of undergoing hypofractionated regimens versus a community center. Ninety-day mortality rates were high in both groups (hypofractionated: 32%; traditional: 24%; p?<?.001).Conclusions
The majority of older GBM patients do not undergo hypofractionated radiation. High 90-day mortality in both groups suggests that hypofractionation may improve the survival-to-treatment time ratio and positively impact patient quality of life. Hypofractionated radiation regimens for GBM should be discussed with older patients and considered for inclusion in efforts to improve the quality and value of cancer care. 相似文献57.
58.
59.
Despite advances in cancer therapeutics and the integration of personalized medicine, the development of chemoresistance in many patients remains a significant contributing factor to cancer mortality. Upon treatment with chemotherapeutics, the disruption of homeostasis in cancer cells triggers the adaptive response which has emerged as a key resistance mechanism. In this review, we summarize the mechanistic studies investigating the three major components of the adaptive response, autophagy, endoplasmic reticulum (ER) stress signaling, and senescence, in response to cancer chemotherapy. We will discuss the development of potential cancer therapeutic strategies in the context of these adaptive resistance mechanisms, with the goal of stimulating research that may facilitate the development of effective cancer therapy. 相似文献
60.